Trials
3 active
3 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Hereditary Angioedema (2 trials), HAE (2 trials), Hereditary Angioedema - Type 1 (2 trials), Hereditary Angioedema - Type 2 (2 trials), Hereditary Angioedema (HAE)
- Main trialPhase 3
- “This study will evaluate the efficacy and safety of ADX-324 in participants with Type 1 or Type 2 hereditary angioedema. The study will also evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD), and health-related quality of life measures.”In the company’s words, NCT06960213 on ClinicalTrials.gov
- Other names
- siRNA
Other drugs for Hereditary Angioedema
- DonidalorsenIonis Pharmaceuticals, Inc. · Phase 3
- NavenibartAstria Therapeutics, Inc. · Phase 3
- DeucrictibantPharvaris Netherlands B.V. · Phase 3
- BerotralstatBioCryst Pharmaceuticals · Phase 3
- NTLA-2002Intellia Therapeutics · Phase 3
- BW-20805Shanghai Argo Biopharmaceutical Co., Ltd. · Phase 2
Coming up3
- 30 Nov 2027Phase 3 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 1/2 trial completes · ClinicalTrials.gov
- 30 Jun 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 30 Nov 2027 | STOP-HAE: A Phase 3 Study of ADX-324 in HAE | |
| Phase 3Recruiting | 30 Jun 2030 | Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) | |
| Phase 1/2Active, not recruiting | 31 Dec 2027 | Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026